Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies
Abstract Background: Eribulin mesylate is currently approved in the United States and Europe for the treatment of metastatic breast cancer (MBC). Scope: The objective of this retrospective study is to find specific predictive criteria related to patient or tumor characteristics in order to select pa...
שמור ב:
Main Authors: | , , , , , , |
---|---|
פורמט: | ספר |
יצא לאור: |
BioExcel Publishing Ltd,
2017-11-01T00:00:00Z.
|
נושאים: | |
גישה מקוונת: | Connect to this object online. |
תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
אינטרנט
Connect to this object online.3rd Floor Main Library
סימן המיקום: |
A1234.567 |
---|---|
עותק 1 | זמין |